Should patients receive a transplant after CAR‑T‑induced remission? When is the optimal timing? Is there hope for a second transplant? Will TP53 gene mutation inevitably result in relapse? These are frequent questions raised by parents of children with hematologic malignancies. In this session, Director Li Zhihui from Beijing Boren Hospital answers these key concerns one by one.